Cofilin 2 (Muscle) (CFL2) (N-Term), (AA 25-54) antibody

Details for Product No. ABIN658038
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Synonyms NEM7, CFL2, wu:fb17d06, wu:fb18d11, wu:fd59f08, wu:fj34b08, xac1, xac2, zgc:77288, cf12
N-Term, AA 25-54
(8), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
(24), (9), (7), (3), (2), (1)
(16), (8), (4)
Clonality (Clone)
Polyclonal ()
Western Blotting (WB), Immunohistochemistry (IHC)
(27), (14), (7), (6), (4), (4), (1)
Pubmed 2 references available
Catalog no. ABIN658038
Quantity 400 µL
291.50 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen This CFL2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 25-54 AA from the N-terminal region of human CFL2.
Clone RB34119
Isotype Ig
Specificity This CFL2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 24-54 amino acids from the N-terminal region of human CFL2.
Predicted Reactivity Cow (Bovine),Mouse (Murine),Pig (Porcine)
Purification This antibody is purified through a protein A column, followed by peptide affinity purification.
Alternative Name CFL2
Background This gene encodes an intracellular protein that is involved in the regulation of actin-filament dynamics. This protein is a major component of intranuclear and cytoplasmic actin rods. It can bind G- and F-actin in a 1:1 ratio of cofilin to actin, and it reversibly controls actin polymerization and depolymerization in a pH-dependent manner. Mutations in this gene cause nemaline myopathy type 7, a form of congenital myopathy. Alternative splicing results in multiple transcript variants.
Synonyms: Cofilin-2,CFL2,
Molecular Weight 18737 DA
Gene ID 1073
UniProt Q9Y281, NP_619579.1, NP_068733.1
Research Area Signaling, Phospho-specific antibodies, Protein Modifications, Neurology, Cell Structure
Application Notes WB = 1:1000, IHC = 1:10-50
Restrictions For Research Use only
Format Liquid
Concentration 0.48 mg/mL
Buffer PBS with 0.09 % (W/V) sodium azide
Preservative Sodium azide
Storage 4 °C/-20 °C
Storage Comment CFL2 Antibody (N-term) can be refrigerated at 2-8 °C for up to 6 months. For long term storage, place the at -20 °C.
Expiry Date 6 months
Supplier Images
anti-Cofilin 2 (Muscle) (CFL2) (N-Term), (AA 25-54) antibody Western blot analysis of CFL2 (arrow) using rabbit polyclonal CFL2 Antibody (N-term) . 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the CFL2 gene.
anti-Cofilin 2 (Muscle) (CFL2) (N-Term), (AA 25-54) antibody (2) CFL2 Antibody (N-term) western blot analysis in human normal Uterus tissue lysates (35ug/lane).This demonstrates the CFL2 antibody detected the CFL2 protein (arrow).
anti-Cofilin 2 (Muscle) (CFL2) (N-Term), (AA 25-54) antibody (3) CFL2 Antibody (N-term) (AP14117a)immunohistochemistry analysis in formalin fixed and paraffin embedded human rectum tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of CFL2 Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.
Background publications Agrawal, Greenleaf, Tomczak et al.: "Nemaline myopathy with minicores caused by mutation of the CFL2 gene encoding the skeletal muscle actin-binding protein, cofilin-2." in: American journal of human genetics, Vol. 80, Issue 1, pp. 162-7, 2006 (PubMed).

Vogel, Wottawa, Farhat et al.: "Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent cofilin phosphorylation." in: The Journal of biological chemistry, Vol. 285, Issue 44, pp. 33756-63, 2010 (PubMed).

Hosts (16), (8), (4)
Reactivities (24), (9), (7), (3), (2), (1)
Applications (27), (14), (7), (6), (4), (4), (1)
Epitopes (8), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top